"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 6 | 6 | 12 |
| 2002 | 28 | 9 | 37 |
| 2003 | 47 | 12 | 59 |
| 2004 | 39 | 15 | 54 |
| 2005 | 29 | 14 | 43 |
| 2006 | 41 | 17 | 58 |
| 2007 | 55 | 37 | 92 |
| 2008 | 53 | 28 | 81 |
| 2009 | 67 | 24 | 91 |
| 2010 | 65 | 28 | 93 |
| 2011 | 55 | 37 | 92 |
| 2012 | 46 | 41 | 87 |
| 2013 | 46 | 43 | 89 |
| 2014 | 40 | 26 | 66 |
| 2015 | 41 | 38 | 79 |
| 2016 | 43 | 32 | 75 |
| 2017 | 40 | 43 | 83 |
| 2018 | 45 | 38 | 83 |
| 2019 | 35 | 38 | 73 |
| 2020 | 23 | 32 | 55 |
| 2021 | 30 | 21 | 51 |
| 2022 | 5 | 37 | 42 |
| 2023 | 3 | 13 | 16 |
| 2024 | 18 | 27 | 45 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 01; 14(11):2135-2161.
-
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care? Expert Rev Hematol. 2024 Nov; 17(11):769-780.
-
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
-
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. J Immunother Cancer. 2024 Sep 23; 12(9).
-
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open. 2024 Sep; 9(9):103689.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.